Insight
Lecomte-Pacific
Photo from Jarushka Naidoo/X

New blood test predicts clinical benefit to IO AND identifies which patient will develop toxicity by Jarushka Naidoo – LUNGevity Foundation

LUNGevity Foundation shared on X/Twitter:

“50% patients develop side effects from immunotx. New blood test predicts clinical benefit to IO AND identifies which patient will develop toxicity and require proactive monitoring. Important question esp for PD-L1>50% Great presentation by Jarushka Naidoo. AACR24″

ImageImage

Image

Image

Source: LUNGevity Foundation/X

AACR24 blood test cancer Jarushka Naidoo LUNGevity Foundation OncoDaily Oncology proactive monitoring toxicity